2020-03-27
Visited : 2421
EnGeneIC Ltd., a pioneering nanobiotechnology company whose proprietary EDV™ nanocell platform enables the targeted delivery of chemotherapeutics and functional nucleic acids directly to tumor cells, has been featured in the 12th volume of InsightsCare – one of the best healthcare magazines worldwide – which has been dedicated to the top ten companies converging nanotechnology and medicine to offer innovative healthcare solutions.
EnGeneIC Limited, a clinical-stage biopharmaceutical company advancing its proprietary EDV™ nanocell platform for targeted cyto-immunotherapy in cancer, today announced that the Company was featured in the publication InsightsCare as one of the 10 most innovative healthcare nanotech companies to watch. The December 2019 Issue (Vol 12) describes the convergence of nanotechnology and medicine and shines a spotlight on pioneering companies using nanotech to drive healthcare innovations.
EnGeneIC was selected based on the company's development of its globally unique EDVTM nanocell, which can carry a payload directly to cancer cells while at the same time promoting an anti-tumour immune response. Added to this the nanocell has a relatively low cost of goods which makes it affordable to patients worldwide and it exhibits none of the attendant toxicity that synthetic particles exhibit.
The Company has earned significant recognition in recent months, being named the 2019 Most Innovative Drug Delivery Company by Fierce Biotech and was awarded the 2019 Australian Financial Review "Most Innovative Company in Australia and New Zealand and Company with the Best Innovation and the Best Innovation Program." To read the full InsightsCare article, click here.
Read the original article on PR Newswire.